Alnylam

Press Releases

Aug 21,2018
Summary ToggleAlnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
PDF Version
Aug 10,2018
Summary ToggleAlnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO™ (patisiran)
PDF Version
Aug 10,2018
Summary ToggleAlnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO™ (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
PDF Version
Aug 03,2018
Summary ToggleAlnylam Announces that the United Kingdom’s MHRA Grants Early Access to Patisiran
PDF Version
Aug 02,2018
Summary ToggleAlnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
Jul 27,2018
Summary ToggleAlnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
PDF Version
Jul 27,2018
Summary ToggleAlnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
PDF Version
Jul 23,2018
Summary ToggleAlnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting
PDF Version
Jul 04,2018
Summary ToggleAlnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
PDF Version
Jun 21,2018
Summary ToggleAlnylam to Host Fifth Annual “RNAi Roundtable” Webcast Series
PDF Version
Jun 20,2018
Summary ToggleAlnylam Expands Senior Leadership Team with Two Key Appointments
PDF Version
Jun 15,2018
Summary ToggleAlnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
PDF Version
Jun 12,2018
Summary ToggleOver 700 Alnylam Employees Volunteer at the Company’s 4th Annual “Helping Hands” Community Service Day
PDF Version
Jun 08,2018
Summary ToggleAlnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Jun 04,2018
Summary ToggleAlnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
PDF Version
May 29,2018
Summary ToggleAlnylam to Webcast Presentations at Upcoming June Investor Conferences
PDF Version
May 15,2018
Summary ToggleAlnylam Appoints Colleen Reitan to the Board of Directors
PDF Version
May 08,2018
Summary ToggleAlnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
PDF Version
May 03,2018
Summary ToggleAlnylam Pharmaceuticals Reports First Quarter 2018 Financial Results and Highlights Recent Period Activity
PDF Version
May 03,2018
Summary ToggleAlnylam Achieves Alignment with FDA on Accelerated Development Path for Lumasiran, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
PDF Version
Displaying 21 - 40 of 987 results
View all releases

Search

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More